FGEN - FibroGen Inc

FGEN - FibroGen Inc

https://www.fibrogen.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million - FibroGen ( NASDAQ:FGEN )

Benzinga • 1 week, 6 days ago • score: 0.39

Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidance Successfully repaid term loan to Morgan Stanley Tactical Value, further simplifying the Company's capital structure

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - FibroGen ( NASDAQ:FGEN )

Benzinga • 4 weeks ago • score: 0.18

Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- FibroGen, Inc.

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

GlobeNewswire • 4 weeks ago • score: 0.11

SAN FRANCISCO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- FibroGen, Inc. ( NASDAQ: FGEN ) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International ( Hong Kong ) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, ...

FibroGen ( FGEN ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.01

FibroGen (FGEN) delivered earnings and revenue surprises of -50.22% and -53.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

FibroGen ( FGEN ) Reports Q1 Loss, Tops Revenue Estimates

Zacks Commentary • 4 months ago • score: 0.02

FibroGen (FGEN) delivered earnings and revenue surprises of -633.33% and 71.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

FibroGen, Inc., a biopharmaceutical company, discovers, develops and markets therapeutic products to treat serious unmet medical needs. The company is headquartered in San Francisco, California.

52W High

$21.94

52W Low

$4.50

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.77

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

61.35

EV/EBITDA (<8 favorable)

-0.17

EV/Revenue (<3 favorable)

13.52

P/S (TTM) (<3 favorable)

6.66

P/B (<3 favorable)

53.83

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

1.58%

Institutions (25–75% balanced)

26.54%

Shares Outstanding

4,043,900

Float

3,623,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

7,346,000

Gross Profit (TTM)

-28,953,000

EPS (TTM)

-21.61

Profit Margin (>10% good)

-0.28%

Operating Margin (TTM) (higher better)

-8.65%

ROE (TTM) (>15% strong)

-10.16%

EPS YoY (Quarterly) (>10% good)

0.54

Revenue YoY (Quarterly) (>8% good)

0.35

Momentum

Bearish momentum

Value

0.9858

Previous

1.0104

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025